2009
The DAC Inhibitor, LBH589, Is Highly Effective in Both Rituximab-Sensitive and Rituximab-Resistant Lymphomas and Enhances the Anti-Tumor Activity of Bortezomib, Other Chemotherapy Agents, and Anti-CD20 Monoclonal Antibodies.
Hernandez-Ilizaliturri F, Marvis C, Maraj I, Chisti M, Gibbs J, Czuczman M. The DAC Inhibitor, LBH589, Is Highly Effective in Both Rituximab-Sensitive and Rituximab-Resistant Lymphomas and Enhances the Anti-Tumor Activity of Bortezomib, Other Chemotherapy Agents, and Anti-CD20 Monoclonal Antibodies. Blood 2009, 114: 2715. DOI: 10.1182/blood.v114.22.2715.2715.Peer-Reviewed Original ResearchPatient-derived primary tumor cellsB-cell lymphomaPrimary tumor cellsChemotherapy agentsAnti-tumor activityMonoclonal antibodiesTumor cellsPolymerase chain reactionLymphoma cell linesCell linesAnti-CD20 Monoclonal AntibodyRoswell Park Cancer InstituteLarge B-cell lymphomaState Cancer CenterCD20 monoclonal antibodySignificant anti-tumor activitySequence of administrationQualitative polymerase chain reactionAnti-tumor effectsPotent treatment strategyNHL cell linesCombination of LBH589Primary lymphoma cellsResistant cell linesSensitive cell linesEfficacy of the DAC inhibitor LBH589 in both rituximab-sensitive and rituximab-resistant lymphomas and effect on the antitumor activity of chemotherapy agents, monoclonal antibodies, and bortezomib
Maraj I, Hernandez-Ilizaliturri F, Chisti M, Czuczman M. Efficacy of the DAC inhibitor LBH589 in both rituximab-sensitive and rituximab-resistant lymphomas and effect on the antitumor activity of chemotherapy agents, monoclonal antibodies, and bortezomib. Journal Of Clinical Oncology 2009, 27: 8576-8576. DOI: 10.1200/jco.2009.27.15_suppl.8576.Peer-Reviewed Original ResearchRituximab-sensitive cell linesRituximab-resistant cell linesCell linesB-cell lymphomaBcl-2 family membersPatient-derived tumor cellsChemotherapy agentsNHL cell linesMonoclonal antibodiesPatient-derived tumour cellsBcl-xL geneCellular processesTumor cellsEffects of LBH589Polymerase chain reactionGene transcriptionGene expressionTarget proteinsAlamar Blue reductionMitochondrial potentialAntitumor activityNegative selectionSequence of administrationQualitative polymerase chain reactionCell titer
2008
The DAC Inhibitor LBH589 Is Highly Effective in Both “Therapy”-Sensitive and -Resistant Lymphomas and Enhances the Anti-Tumor Activity of Chemotherapy Agents, Monoclonal Antibodies, and Bortezomib
Maraj I, Hernandez-Ilizaliturri F, Chisti M, Czuczman M. The DAC Inhibitor LBH589 Is Highly Effective in Both “Therapy”-Sensitive and -Resistant Lymphomas and Enhances the Anti-Tumor Activity of Chemotherapy Agents, Monoclonal Antibodies, and Bortezomib. Blood 2008, 112: 4984. DOI: 10.1182/blood.v112.11.4984.4984.Peer-Reviewed Original ResearchPatient-derived tumour cellsB-cell lymphomaTarget proteinsAnti-tumor activitySequence of administrationNon-histone proteinsChemotherapy agentsCell linesTumor cellsMonoclonal antibodiesCellular processesTranscription factorsEffects of LBH589Gene transcriptionLymphoma cellsAlamar Blue reductionDeacetylasesMitochondrial potentialCell deathRituximab-resistant cell linesSchedule of administrationSignificant anti-tumor activityDAC activityPatient-derived tumor cellsNegative selection